Ovid Therapeutics Inc. is a biopharmaceutical company focused on improving the lives of people with epilepsies and brain conditions with seizure symptoms. It advances a pipeline of novel, targeted small molecule candidates that modulate factors involved in neuronal hyperexcitability. Key developments include OV888 (GV101), a ROCK2 inhibitor for cerebral cavernous malformations; OV329, a GABA-aminotransferase inhibitor for treatment-resistant seizures; and OV350, a KCC2 transporter activator for epilepsies and psychiatric conditions. It also develops soticlestat, a cholesterol 24-hydroxylase inhibitor for Dravet and Lennox-Gastaut syndromes. The OVID average annual return since 2017 is shown above.
The Average Annual Return on the OVID average annual return since 2017 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether OVID average annual return since 2017 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the OVID average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free OVID Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
